NFKB1 and myeloproliferative disorder: Combination JAK/STAT inhibition and BET inhibition treatment has been shown to synergistically block NF-kB hyperactivation and inflammatory cytokine production, thereby attenuating disease burden and reversing bone marrow fibrosis in mouse models of MPN [47].